Yazdi K. Pithavala

ucsd skaggs school of pharmacy

H指数:27

被引数:3,125

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

AI-Powered Lesion-Level Tumor Growth Inhibition Modeling Improves Model Stability and Prognostic Association With PFS

AI驱动的病灶级肿瘤生长抑制建模提高了模型稳定性并与PFS预后关联

cpt: pharmacometrics & systems pharmacology

IF0

2026-06-130

Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model

恩考拉非尼在健康受试者和BRAF V600突变实体瘤患者中的群体药代动力学建模：一种半机制性自诱导模型

Clinical Pharmacokinetics

IF4

2026-03-120

OAAI

Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules

FDA批准的肿瘤学小分子药物的 Landscape analysis of adverse events and dose intensity

CANCER CHEMOTHERAPY AND PHARMACOLOGY

IF2.3

2025-01-040

Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-05-164

OAAI

A literature review of liver function test elevations in rifampin drug-drug interaction studies

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2022-05-096

OAAI

Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity

TOXICOLOGICAL SCIENCES

IF4.1

2021-05-216

PREAI

Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-02-0114

OAAI

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants (vol 37, pg 745, 2020)

ADVANCES IN THERAPY

IF4

2020-09-100

PREAI

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

TARGETED ONCOLOGY

IF4

2020-02-1484

OAAI

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants

ADVANCES IN THERAPY

IF4

2019-12-2028

PREAI

The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants

INVESTIGATIONAL NEW DRUGS

IF2.7

2019-11-1418

PREAI

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib

TARGETED ONCOLOGY

IF4

2015-09-2416

OAAI

Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer

CANCER RESEARCH

IF16.6

2015-08-010

PRE

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

ANNALS OF ONCOLOGY

IF65.4

2015-07-0169

OAAI

Axitinib plasma pharmacokinetics and ethnic differences

INVESTIGATIONAL NEW DRUGS

IF2.7

2015-02-0824

PREAI

Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic/Pharmacodynamic and Quality-of-Life Assessments

CANCER

IF5.1

2014-05-2098

PREAI

Population pharmacokinetic analysis of axitinib in healthy volunteers

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2014-02-2128

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

阿昔替尼 (AG-013736) 联合吉西他滨治疗晚期胰腺癌的I期研究

INVESTIGATIONAL NEW DRUGS

IF2.7

2011-06-1417

PREAI

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

INVESTIGATIONAL NEW DRUGS

IF2.7

2010-08-2651

OAAI

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

INVESTIGATIONAL NEW DRUGS

IF2.7

2010-07-0257

OAAI

Yazdi K. Pithavala

个人简介

教育背景

工作经历

荣誉奖项

研究方向